1. Scrip

Akero Thinks It Will Produce A Next-Wave Therapy For NASH With Former Amgen Compound

 
• By Joseph Haas

Akero is entering the NASH race with a mechanism it thinks will be more powerful than current Phase III candidates and offer better efficacy than two other FGF-targeted candidates now in Phase II.

Jonathan Young of Akero
Akero CEO Jonathan Young

Newly unveiled Akero Therapeutics Inc. is jumping into the crowded non-alcoholic steatohepatitis (NASH) drug development race with a Phase II-ready FGF21 analog licensed from Amgen Inc. that it believes will offer best-in-class potential by addressing both metabolic and fibrotic aspects of the disease.

The Cambridge, Mass.-based firm announced both a $65m Series A financing and the licensing of AKR-001 on June 25

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.